TY - JOUR
T1 - Full immunologic reconstitution following nonconditioned bone marrow transplantation for canine X-linked severe combined immunodeficiency
AU - Felsburg, Peter J.
AU - Somberg, Richard L.
AU - Hartnett, Brian J.
AU - Suter, Steven F.
AU - Henthorn, Paula S.
AU - Moore, Peter F.
AU - Weinberg, Kenneth I.
AU - Ochs, Hans D.
PY - 1997/10/15
Y1 - 1997/10/15
N2 - Bone marrow transplantation in human X-linked severe combined immunodeficiency (XSCID) without protransplant conditioning results in engraftment of donor T cells and reconstitution of T-cell function but engraftment of few, if any, donor B cells and poor reconstitution of humoral immune function. Since bone marrow transplantation remains the most effective treatment of XSCID patients, better strategies are necessary to achieve optimum long-term results. Canine XSCID, like human XSCID, is due to mutations in the common γ, chain (γc) gene and has clinical and immunologic features identical to those of human XSCID, making it a true homolog of the human disease. We have successfully performed bone marrow transplantation in three XSCID dogs without pretransplant conditioning, using untreated bone marrow cells from mixed lymphocyte culture-nonreactive normal littermates. Unlike the experience in human XSCID patients, all three dogs engrafted both donor B and T cells and attained full reconstitution of immunologic function. Normal percentages of T cells and T-cell mitogenic responses were attained by 3 months posttransplant. CD3+ T cells after transplantation expressed the CD45RA isoform indicating that the cells were recent thymic emigrants derived from immature progenitors. Serum IgG levels were within normal range by 5 months posttransplant. Immunization with the T-dependent antigen, bacteriophage ΦX174, demonstrated normal antibody tilers, immunologic memory, and class-switching. Polymerase chain reaction (PCR) analysis of the γc locus showed that 100% of circulating T cells and 30% to 50% of circulating B celts were donor-derived. None of the dogs developed clinically evident graft-versus-host disease (GVHD). Thus, canine XSCID provides a model to determine the optimal conditions for bone marrow transplantation in human patients, and to develop and test strategies for somatic gens therapy.
AB - Bone marrow transplantation in human X-linked severe combined immunodeficiency (XSCID) without protransplant conditioning results in engraftment of donor T cells and reconstitution of T-cell function but engraftment of few, if any, donor B cells and poor reconstitution of humoral immune function. Since bone marrow transplantation remains the most effective treatment of XSCID patients, better strategies are necessary to achieve optimum long-term results. Canine XSCID, like human XSCID, is due to mutations in the common γ, chain (γc) gene and has clinical and immunologic features identical to those of human XSCID, making it a true homolog of the human disease. We have successfully performed bone marrow transplantation in three XSCID dogs without pretransplant conditioning, using untreated bone marrow cells from mixed lymphocyte culture-nonreactive normal littermates. Unlike the experience in human XSCID patients, all three dogs engrafted both donor B and T cells and attained full reconstitution of immunologic function. Normal percentages of T cells and T-cell mitogenic responses were attained by 3 months posttransplant. CD3+ T cells after transplantation expressed the CD45RA isoform indicating that the cells were recent thymic emigrants derived from immature progenitors. Serum IgG levels were within normal range by 5 months posttransplant. Immunization with the T-dependent antigen, bacteriophage ΦX174, demonstrated normal antibody tilers, immunologic memory, and class-switching. Polymerase chain reaction (PCR) analysis of the γc locus showed that 100% of circulating T cells and 30% to 50% of circulating B celts were donor-derived. None of the dogs developed clinically evident graft-versus-host disease (GVHD). Thus, canine XSCID provides a model to determine the optimal conditions for bone marrow transplantation in human patients, and to develop and test strategies for somatic gens therapy.
UR - http://www.scopus.com/inward/record.url?scp=0030796576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030796576&partnerID=8YFLogxK
M3 - Article
C2 - 9376605
AN - SCOPUS:0030796576
VL - 90
SP - 3214
EP - 3221
JO - Blood
JF - Blood
SN - 0006-4971
IS - 8
ER -